Catalent Pharma Solutions, Inc., founded in 2007 and headquartered in Somerset, New Jersey, is a leading global provider of advanced drug delivery technologies, development, and manufacturing solutions for pharmaceuticals, biologics, and consumer health products. The company offers a range of services including formulation development, clinical trial materials, and commercial manufacturing, making it a crucial partner in the life sciences industry.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| CTLT 2.38% 2028-03-01 EURCatalent Pharma Solutions, Inc. | United States | 2028-03-01 | 2.375 | 2.47 |
| CTLT 2.38% 2028-03-01 EURCatalent Pharma Solutions, Inc. | United States | 2028-03-01 | 2.375 | 2.47 |
| CTLT 3.13% 2029-02-15 USDCatalent Pharma Solutions, Inc. | United States | 2029-02-15 | 3.125 | — |
| CTLT 3.13% 2029-02-15 USDCatalent Pharma Solutions, Inc. | United States | 2029-02-15 | 3.125 | — |
| CTLT 3.50% 2030-04-01 USDCatalent Pharma Solutions, Inc. | United States | 2030-04-01 | 3.500 | — |
| CTLT 3.50% 2030-04-01 USDCatalent Pharma Solutions, Inc. | United States | 2030-04-01 | 3.500 | — |
| CTLT 5.00% 2027-07-15 USDCatalent Pharma Solutions, Inc. | United States | 2027-07-15 | 5.000 | 31.75 |
| CTLT 5.00% 2027-07-15 USDCatalent Pharma Solutions, Inc. | United States | 2027-07-15 | 5.000 | 29.85 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Catalent has a history of bond issuances aimed at financing strategic growth, with notable offerings beginning in 2014 when it issued $350 million in senior unsecured notes. In recent years, the company successfully entered the capital markets with a $500 million issuance in 2021, which was utilized for debt refinancing and enhancing its operational capabilities. Current yields on Catalent’s bonds are competitive within the industry, and the company’s investment-grade rating reflects its strong financial health and commitment to growth.